Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 31, 2006
Correlation between molecular metastases in sentinel lymph nodes of breast cancer patients and St Gallen risk categoryP Gimbergues, M M Dauplat, A Cayre, et al.
Cancer Medicine|July 6, 2023
Compliance to genomic test recommendations to guide adjuvant chemotherapy decision-making in the case of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, in real-life settingsD Hequet, N Hajjaji, E Charafe-Jauffret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2012
Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular studyT André, H Blons, M Mabro, et al.
International Journal of Cancer|December 10, 2015
Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancerJ M Nabholtz, N Chalabi, N Radosevic-Robin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 29, 2013
Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT networkM Beau-Faller, N Prim, A-M Ruppert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2014
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impactJ M Nabholtz, C Abrial, M A Mouret-Reynier, et al.
ESMO Open|May 1, 2024
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trialF Penault-Llorca, F Dalenc, S Chabaud, et al.
ESMO Open|September 15, 2023
Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across EuropeP Hofman, F Calabrese, I Kern, et al.
Pageof 2